Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 14/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2359169 | 0.75 | MAPT (0.46) | CACNA1HCACNA1GCACNA1ISOS1CYP11B1 | |
| SCHEMBL6410513 | 0.74 | CACNA1H (0.39) | CACNA1HCACNA1GCACNA1IPDE2ACYP11B1 | |
| SCHEMBL7966541 | 0.74 | LMNA (0.48) | CACNA1HCACNA1GCACNA1IPDE2ATRPV4 | |
| SCHEMBL6409767 | 0.73 | CYP11B1 (0.64) | CACNA1HCACNA1GCACNA1ITRPV4CYP11B1 | |
| SCHEMBL32683820 | 0.71 | FGFR1 (0.43) | CACNA1HCACNA1GCACNA1IPDE2ATRPV4 | |
| SCHEMBL31674269 | 0.71 | APP (0.46) | CACNA1HCACNA1GCACNA1ITRPV4 | |
| SCHEMBL32684047 | 0.70 | PDE2A (0.39) | CACNA1HCACNA1GCACNA1IPDE2AP2RX7 | |
| SCHEMBL2724753 | 0.68 | TRPV4 (0.53) | TRPV4CYP11B1CYP11B2 | |
| SCHEMBL7713277 | 0.68 | CYP11B1 (0.46) | CYP11B1CYP11B2 | |
| SCHEMBL6417203 | 0.67 | DAO (0.40) | CACNA1HCACNA1GCACNA1ITRPV4CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1090012-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-6562823-B1 | Inhibition of farnesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar | MERCK & CO., INC. | 2003-05-13 | — | — | US | disclosed |
| US-20020193283-A1 | Inhibitors of prenyl-protein transferase | DINSMORE CHRISTOPHER J (US) | 2002-12-19 | — | — | US | disclosed |
| US-20020052363-A1 | Inhibitors of prenyl-protein transferase | DINSMORE CHRISTOPHER J (US) | 2002-05-02 | — | — | US | disclosed |
| US-20020052380-A1 | Inhibitors of prenyl-protein transferase | DINSMORE CHRISTOPHER J (US) | 2002-05-02 | — | — | US | disclosed |
| US-20020010184-A1 | Inhibitors of prenyl-protein transferase | DINSMORE CHRISTOPHER J (US) | 2002-01-24 | — | — | US | disclosed |
| WO-2001060368-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-08-23 | — | — | WO | disclosed |
| WO-2001060458-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-08-23 | — | — | WO | disclosed |
| WO-2001060369-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-08-23 | — | — | WO | disclosed |
| WO-2001060815-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-08-23 | — | — | WO | disclosed |
| EP-1090012-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000016778-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000001702-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010184-A1 | Inhibitors of prenyl-protein transferase | FNTA, FNTB, ZMPSTE24 | CACNA1H 4079/4885CACNA1G 4261/4885CACNA1I 3518/4885 |
| US-20020193283-A1 | Inhibitors of prenyl-protein transferase | FNTA, FNTB, PTAR1 | CACNA1H 4625/4885CACNA1G 4514/4885CACNA1I 4110/4885 |
| US-20020052363-A1 | Inhibitors of prenyl-protein transferase | FNTA, FNTB, PTAR1 | CACNA1H 4625/4885CACNA1G 4514/4885CACNA1I 4110/4885 |
| US-20020052380-A1 | Inhibitors of prenyl-protein transferase | FNTA, FNTB, GGPS1 | CACNA1H 4564/4885CACNA1G 4483/4885CACNA1I 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.